The physicians at 15 brain cancer centers in eight countries will now be able to treat recurrent glioblastoma patients using the anti-mitotic therapy on prescription order outside clinical trials.
Novocure chief commercial officer Peter Melnyk said that the company will be working with such world-renowned oncology experts to provide NovoTTF Therapy to recurrent glioblastoma patients.
"Training leading physicians at these medical centers is the first step in the commercial launch of our product in Europe and Israel," Melnyk added.
NovoTTF-100A system delivers NovoTTF therapy and is designed for continuous use by patients. In vitro and in vivo studies have shown that the portable, non-invasive medical device slows and reverses tumor growth by inhibiting mitosis.
In the EU, Switzerland and Australia, the NovoTTF-100A system is approved for the treatment of adult patients, 18 years of age or older, with recurrent glioblastoma who have progressed after surgery, radiotherapy and Temozolomide treatment for their primary disease.
In Israel, the device is approved for the treatment of adult patients, 22 years of age or older, with histologically-confirmed glioblastoma, following histologically – or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy.
